Development of Non-Invasive MRI Applications for Liver Fibrosis and Inflammation
NCT ID: NCT05168982
Last Updated: 2023-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2021-08-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Magnetic resonance effect can be used to obtain the molecular-level information on the biochemical properties of human tissues. The investigators will develop non-invasive quantitative MRI technologies to evaluate and stage liver fibrosis and inflammation. Our approaches are based on the endogenous contrast mechanism and thus do not need to inject an MRI contrast agent. Our approaches can be implemented on a regular MRI scanner and do not need any extra hardware. To enable the technology for routine clinical use, the investigators will develop fully automated post-processing techniques for the proposed MRI acquisition approaches. The investigators will perform multi-center clinical studies in Hong Kong and mainland China to validate our imaging measurements by histopathologic results from liver biopsies on patient cohorts.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis
NCT04429100
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
NCT05384652
Quantitative Diagnosis of Liver Fibrosis on Multiparametric MRI
NCT03176797
68Ga-FAPI PET/CT in Liver Fibrosis Patients
NCT04533828
Quantitative MRI Imaging in Diffuse Liver Diseases
NCT04626492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic liver disease (CLD) patients at stage A0 of liver inflammation
No interventions assigned to this group
Chronic liver disease (CLD) patients at stage A1 of liver inflammation
No interventions assigned to this group
Chronic liver disease (CLD) patients at stage A2 of liver inflammation
No interventions assigned to this group
Chronic liver disease (CLD) patients at stage A3 of liver inflammation
No interventions assigned to this group
Chronic liver disease (CLD) patients at stage F0 of liver fibrosis
No interventions assigned to this group
Chronic liver disease (CLD) patients at stage F1 of liver fibrosis
No interventions assigned to this group
Chronic liver disease (CLD) patients at stage F2 of liver fibrosis
No interventions assigned to this group
Chronic liver disease (CLD) patients at stage F3 of liver fibrosis
No interventions assigned to this group
Chronic liver disease (CLD) patients at stage F4 of liver fibrosis
No interventions assigned to this group
healthy subjects
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic liver disease (CLD) patients at different stages of liver inflammation (A0-3) and liver fibrosis (F0-4).
* CLD patients who have indications and are scheduled to undergo liver biopsy.
Exclusion Criteria
* Patients who had undergone liver transplantation before enrollment.
* Any contraindications to either liver biopsy or MRI scan.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chen Weitian
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Chinese University of Hong Kong, Prince of Wale Hospital
Hong Kong, Shatin, Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021.372
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.